Drugs used for treatment in the clinic also have side effects. As one of these drugs, Methotrexate (MTX) is a folate antagonist antimetabolite that has a wide range of uses in diseases such as cancer and non-cancer autoimmune diseases, inflammatory diseases and abortus. MTX is included in the treatment of diseases such as rheumatoid arthritis, while these patients are known to tend to renal function disorders. Because of this, patients who receive MTX treatment also receive renal function tests periodically and during the treatment process, they are initiated leucovorin, hydration and glucarpidase rescuers, if necessary. Morin hydrate (MH) compound is known to have multi-biological effects such as antioxidant and anti-inflammatory effects. The present study aimed to investigate the effects of a single-effective dose of MTX (20 mg/kg) induced renal toxicity by using the properties of MH (100 mg/kg) compound. In addition to histopathology, renal function tests and oxidative stress/antioxidant levels were evaluated. It was found that while MH improved MTX-induced renal function and structural changes, it also improved MTX-induced renal toxicity significantly. The protective role of MH against MTX-induced renal toxicity was provided due to its free radical scavenging property and by increasing cellular antioxidant defense. We believe that MH is a candidate for protection against renal toxicity of MTX.
Key words: Renal, morin hydrate, methotrexate, oxidative stress, antioxidant
|
